Meanwhile, another $70 million to $80 million of the IPO proceeds is expected to fund the launch a phase 1b study of its ...

Immunology biotech Agomab Therapeutics and eye-focused SpyGlass Pharma have both unveiled their intentions to go public, in ...

Two more biopharma companies—the hair-growth specialist Veradermics and cancer-focused Eikon Therapeutics—have announced ...

The BIM-IOL is designed to be implanted during cataract surgery, tackling IOP while restoring vision, and SpyGlass is also ...

With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in the last two years.

Hair loss–focused Veradermics and cancer biotech Eikon follow the lead of Aktis Oncology, which last week announced a $318 ...

The two IPOs, which follow radiopharma specialist Aktis Oncology's filing last week, have investors and industry watchers ...

TheraVectys SA is considering an initial public offering in Hong Kong, according to people familiar with the matter, a rare move for a non-Chinese biotech firm despite a wave of listings in the Asian ...

Startup Parabilis Medicines has raised $305 million in new funding, money that will help bring its lead drug for a variety of cancers into late-stage testing.

A surge in deals and financings had the industry abuzz heading into this year’s J.P. Morgan Healthcare Conference. But some ...

By Sriparna Roy and Christy Santhosh Jan 14 (Reuters) - Investors are eyeing a rebound in the U.S. biotech sector in 2026, as ...

Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...